View in EDS HTML Full Text PDF Full Text

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.

Saved in:

Bibliographic Details
Title:	Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Authors:	Shao, Hui¹ (AUTHOR), Alsaleh, Abdul Jabbar Omar² (AUTHOR), Dex, Terry³ (AUTHOR), Lew, Elisheva⁴ (AUTHOR), Fonseca, Vivian^5,6 (AUTHOR) vfonseca@tulane.edu
Source:	Diabetes Therapy. Sep2022, Vol. 13 Issue 9, p1659-1670. 12p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	18696953
DOI:	10.1007/s13300-022-01300-5